[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fallopian-tube-carcinoma-stage-iii\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fallopian-tube-carcinoma-stage-iii":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100495907","phase-3-nab-paclitaxel-versus-sb-taxanes-as-first-line-treatment-in-advanced-ovarian-cancer-100495907",false,"NCT05737303","Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer","Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Epithelial ovarian cancer\u002Ftubal cancer\u002Fperitoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen, and was classified as stage III-IV according to FIGO（International Federation of Gynecology and Obstetrics）stage\n2. Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points\n3. Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment\n4. Written informed consent\n5. Expected survival ≥6 months\n6. The disease met the criteria for Efficacy Evaluation of solid tumors (RECIST 1.1)\n7. Be able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation.\n\nExclusion Criteria:\n\n1. Patients with low malignant potential ovarian tumors;\n2. Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;\n3. Patients who have previously received chemotherapy or radiotherapy for pelvic cavity;\n4. Patients with central nervous system metastasis or peripheral neuropathy \\> grade 1;\n5. Patients with severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at the time of screening;\n6. Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); According to NYHA（New York Heart Association） criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) \\\u003C 55% indicated by color Doppler ultrasonography;\n7. Uncontrolled systemic infection requiring anti-infective treatment;\n8. Arteriovenous thrombosis events occurring within 6 months before randomization, such as cardiovascular and cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction, myocardial infarction), deep vein thrombosis and pulmonary embolism;\n9. Patients who are allergic to the active ingredients or excipients of albumin paclitaxel and carboplatin for injection;\n10. Pregnant or lactating women;\n11. Those who were considered unsuitable for inclusion by the researchers.","FEMALE","18 Years","75 Years",{"count":20,"type":21},538,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.",[27,28,29,30,31,32],"Epithelial Ovarian Carcinoma Stage III","Epithelial Ovarian Carcinoma Stage IV","Fallopian Tube Carcinoma Stage III","Fallopian Tube Carcinoma Stage IV","Primary Peritoneal Carcinoma Stage III","Primary Peritoneal Carcinoma Stage IV","RECRUITING","2025-02-09",{"date":36,"type":37},"2025-02-11","ACTUAL",{"date":39,"type":37},"2023-11-27",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Women's Hospital School Of Medicine Zhejiang University","OTHER",11]